ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an oral calcium released activated calcium modulator ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. The company also retains rights in various indications and markets to its other drug candidates and programs, which include STA-9090, an Hsp90 inhibitor that is in Phase 1 development; elesclomol, an oxidative stress inducer for the treatment of cancer; and apilimod, an oral IL-12/23 inhibitor, which is in Phase 2 for rheumatoid arthritis. In addition, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent that is in preclinical development. The company was incorporated in 2000 and is based in Lexington, Massachusetts.

Longhua Hospital Shanghai University of TCM, a subsidiary of Shanghai University of Traditional Chinese Medicine, is a company headquartered in Shanghai, China. The firm provides hospital services.

Jianmin Pharmaceutical Group Co., Ltd. engages in the research, development, manufacturing, wholesale and retail of pharmaceutical products. The company manufactures tablets, hard capsules, granules, pills, syrup, powder, decoction, wine, and mixture, beverages, health foods, and cosmetics. It also provides Chinese medicine diagnosis and treatment services. The company was founded on June 1, 1953 and is headquartered in Wuhan, China.

Hebei Yiling Pharmaceutical Research Institute Co., Ltd., established on 2001-04-19, Business scope includes Chinese patent medicine,Medicine and health products,Traditional Medical Devices,Western medicine,Biological product,Research and Development of Sanitary Dressing;technical consulting,Serve,transfer.(Those requiring special approval shall not operate without approval)

Hebei Tianshi Pharmaceutical Technology Development Co., Ltd., established on 2005-04-01, Business scope includes traditional Chinese medicine,Western medicine,Biological product,Technology research and development of health care products,technical consulting,Technology Transfer and Technical Services(National law,Matters prohibited or restricted by regulations and decisions of the State Council,Not allowed to operate;Matters requiring approval from other departments,after approval,before operating)

Zhanjiang Guangyi Asset Management Co., Ltd., established on 1992-04-10, Business scope includes school asset management;Pharmaceutical project investment;Information Consulting(Except securities and futures investment,Education and training consulting and other consulting services involving pre-approval and exclusive control);Transformation of medical science and scientific and technological achievements,transfer,Incubation and Consulting Services;Medical Technology,medicine,Reagent,Software system and medical device R&D services;Science and Technology Information Consulting and Communication Services;medicine,Sales of Medical Devices(Limited to the operation of subordinate branches).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Michi Co. Ltd. engages in the production and sale of nail chips. It conducts its business through the e-commerce site michi nail. The company was founded by Shun Nakazaki on June 25, 2012 and is headquartered in Tokyo, Japan.

Shijiazhuang Zangnuo Pharmaceutical Co., Ltd., established on 2004-06-07, The business scope includes hard capsules,pill(water pill)Production and sales of pharmaceuticals;special dietary food,Healthy food,instant food,Confectionery,Tea and related products,condiment,Beverage production and sales;Chinese herbal medicine,Processing and sales of Chinese herbal medicines;Production and sales of cosmetics;unprocessed primary agricultural products,Disinfectant,household appliances,Daily necessities,crafts,Sales of Fitness Equipment;medical instruments,Research and development of masks,production and sales;Biotechnology,New Tibetan medicine,R&D and technology transfer of new traditional Chinese medicine and health food;R&D and technology transfer of pharmaceutical technology,technical consulting;Self-operated import and export business of products distributed by the company;technology incubator,Construction of Science and Technology Park,Operation and Management.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Wuhan Jianmin Traditional Chinese Medicine Eng'g Co. Ltd., part of Jianmin Pharmaceutical Group Co., Ltd., is a company headquartered in Wuhan, China, that manufactures, distributes and researches traditional Chinese medicine. It was acquired by Jianmin Pharmaceutical Group Co., Ltd. on December 12, 2011 for $50.28 million.

Yangtze River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd., established on 2001-01-08, Business scope includes licensed projects:pharmaceutical production;Drug Wholesale;Drug retail;Production of Class II Medical Devices;Production of Class III Medical Devices;food production;Health food production;Health food sales;food business;Class III medical device business;Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Production of Class I Medical Devices,Class I medical device,Class II medical device,disinfectant(Free of Hazardous Chemicals)promotion of,Car rental,Engaged in technology research and development in the field of medical technology,technology transfer,technical consulting,Technical Services,The following limited branch operations:Catering Services,accommodation service,Conference and Exhibition Services.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Xinjiang Huashidan Pharmaceutical Co., Ltd., established on 1998-12-08, Business scope includes licensed projects:pharmaceutical production;Drug retail;Drug import and export;Drug Wholesale;Drug internet information service;Health food production;food production;Food Internet Sales;food sales;Chinese Herbal Pieces Decoction Service;Veterinary drug business;Veterinary drug production;Production of tea products;Cosmetic production;Drinking water made and sold now.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Production of Chinese herbal extracts;Chinese herbal medicine planting;Chinese herbal medicine acquisition;real estate herbal medicine(Does not contain Chinese herbal medicine)buy and sell;Pharmaceutical commissioned production;Healthy food(prepackaged)Sales;food sales(Only sell prepackaged food);Food Internet Sales(Only sell prepackaged food);Food import and export;Import and export;Technology Import and Export;Loading and unloading;Cosmetics Wholesale;Cosmetics Retail;General Cargo Warehousing Services(Does not contain hazardous chemicals and other items that require approval);Operation of Road Freight Transport Station;Heat production and supply.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shaanxi Haipu Pharmaceutical Co. Ltd. is a company headquartered in Weinan, China. The firm engages in research, development, production and marketing of medicine and health products.

Zhongshan Laibo Ruichen Bio-Pharmaceutical Co., Ltd., established on 2021-01-07, Business scope includes general items:Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology Import and Export;Import and export.(The above business scope involves:Import and export of goods or technology(Except for the import and export of goods and technologies that are prohibited by the state or involve administrative approval)) (Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:pharmaceutical production;Pharmaceutical commissioned production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)[The above business scope does not include:Research and development of rare and unique precious varieties in China,farming,Planting and production of related propagating material(including farming,animal husbandry,Good Genes of Aquaculture);crop,Breeding livestock and poultry,Selection and Breeding of Transgenic Varieties of Aquatic Seedlings and Their Transgenic Seeds(Seedling)Production;Invest in Human Stem Cells,Development and application of genetic diagnosis and treatment technology;Invest in the steaming of Chinese herbal decoction pieces,saute,broil,The application of calcining and other processing technologies and the production of secret prescription products of Chinese patent medicines](The above projects do not involve special management measures for foreign investment access)

Changchun Renren Pharmaceutical Co., Ltd., established on 2014-04-16, The business scope includes the cultivation of Chinese herbal medicines,buy,Sales,and related technology research and development;Acquisition of agricultural and sideline products,Sales(except food);Chinese Herbal Medicine(Contains direct oral tablets)Production,Sales;Chinese herbal extracts and granules,food,Healthy food,cosmetic,Health Supplies,Animal Feed and Feed Additives,medical instruments,hygiene products,Disinfection supplies(Disinfection products),Research on Traditional Chinese Medicine and Health Products,Production,Sales;medicine(Including traditional Chinese medicine and chemical medicine),Research and development of biological products;Production of pharmaceutical and food packaging materials,Sales;technology,Goods import and export business;wine production,research and development,Sales;Research and development and sales of veterinary drugs;Unit logistics management service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Asahi Kasei Pharma Corp., a subsidiary of Asahi Kasei Corp., is a company headquartered in Tokyo, Japan, that functions as an alternative investment manager. The firm was founded in 2003.\nThe company says this about itself: Asahi Kasei Pharma Corporation, headquartered in Tokyo, Japan, is a research-based health care innovator that discovers, develops, manufactures, and markets pharmaceuticals and diagnostic products. Asahi Kasei Pharma is a wholly owned business unit of Asahi Kasei Corporation, a US $20 billion technology company, that provides innovative, science-based solutions to a diverse range of markets including healthcare, chemicals and fibers, housing and construction materials, and electronics.

Nanjing Xingyin Pharmaceutical Group Co. Ltd. is a private company headquartered in Nanjing, China, that manufactures and distributes pharmaceuticals.